Journal article icon

Journal article

Long-term hospitalisation rates among 5-year survivors of Hodgkin Lymphoma in adolescence or young adulthood - A nationwide cohort study.

Abstract:
In the present study, we report on the full range of physical diseases acquired by survivors of Hodgkin lymphoma diagnosed in adolescence or young adulthood. In a Danish nationwide population-based cohort study, 1768 five-year survivors of Hodgkin lymphoma diagnosed at ages 15–39 years during 1943-2004 and 228,447 comparison subjects matched to survivors on age and year of birth were included. Hospital discharge diagnoses and bed-days during 1977-2010 were obtained from the Danish Patient Register for 145 specific disease categories gathered in 14 main diagnostic groups. The analysis was conducted separately on three sub-cohorts of survivors, i.e. survivors diagnosed 1943-1976 for whom we had no information on re-hospitalisation for Hodgkin lymphoma and survivors diagnosed 1977-2004, split into a subcohort with no expected relapses and a subcohort for whom a re-hospitalisation for Hodgkin lymphoma indicated a relapse. The overall standardised hospitalisation rate ratios (RRs) were 2.0 (95% confidence interval (CI), 1.9-2.1), 1.5 (1.4-1.6) and 2.9 (2.6-3.1) respectively, and the corresponding RRs for bed-days were 3.5 (3.4-3.5), 1.8 (1.8-1.9) and 10.4 (10.3-10.6). Highest RRs were seen for non-malignant haematological conditions (RR: 2.6; 3.1 and 9.7), malignant neoplasms (RR: 3.2; 2.5 and 4.7) and all infections combined (RR: 2.5; 2.2 and 5.3). Survivors of Hodgkin lymphoma in adolescence or young adulthood are at increased risk for a wide range of diseases that require hospitalisation. The risk depends on calendar period of treatment and on whether the survivors were re-hospitalised for Hodgkin lymphoma, and thus likely had a relapse.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1002/ijc.30655

Authors

More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author


More from this funder
Funding agency for:
Aznar, M
Cutter, D
Darby, S
Grant:
C8225/A21133
C8225/A21133
C8225/A21133


Publisher:
Wiley
Journal:
International Journal of Cancer More from this journal
Volume:
140
Issue:
10
Pages:
2232–2245
Publication date:
2017-02-01
Acceptance date:
2017-02-02
DOI:
ISSN:
1097-0215


Language:
English
Keywords:
Pubs id:
pubs:681357
UUID:
uuid:674999ef-3b50-40e2-8083-c46a55503f89
Local pid:
pubs:681357
Deposit date:
2017-03-01
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP